000294330 001__ 294330
000294330 005__ 20250228163922.0
000294330 0247_ $$2doi$$a10.1016/j.trecan.2024.10.006
000294330 0247_ $$2pmid$$apmid:39448335
000294330 0247_ $$2ISSN$$a2405-8033
000294330 0247_ $$2ISSN$$a2405-8025
000294330 037__ $$aDKFZ-2024-02163
000294330 041__ $$aEnglish
000294330 082__ $$a610
000294330 1001_ $$0P:(DE-He78)7eaaf5131f5096c7ff7de12dde4ceca5$$aSuarez-Carmona, Meggy$$b0$$eFirst author$$udkfz
000294330 245__ $$aNeoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer.
000294330 260__ $$aAmsterdam$$bElsevier$$c2024
000294330 3367_ $$2DRIVER$$aarticle
000294330 3367_ $$2DataCite$$aOutput Types/Journal article
000294330 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1740749145_27535
000294330 3367_ $$2BibTeX$$aARTICLE
000294330 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294330 3367_ $$00$$2EndNote$$aJournal Article
000294330 500__ $$a#EA:D196#LA:D196# / 2024 Dec;10(12):1093-1094 / HI-TRON / SPOTLIGHT
000294330 520__ $$aNeoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.
000294330 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000294330 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294330 650_7 $$2Other$$aMSI
000294330 650_7 $$2Other$$acolorectal cancer
000294330 650_7 $$2Other$$adMMR
000294330 650_7 $$2Other$$aimmune checkpoint inhibition
000294330 650_7 $$2Other$$aneoadjuvant therapy
000294330 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b1$$eLast author$$udkfz
000294330 773__ $$0PERI:(DE-600)2852626-0$$a10.1016/j.trecan.2024.10.006$$gp. S2405803324002255$$n12$$p1093-1094$$tTrends in cancer$$v10$$x2405-8033$$y2024
000294330 8767_ $$8E-2024-01562-b$$92025-02-19$$d2025-02-20$$eHybrid-OA$$jZahlung erfolgt
000294330 909CO $$ooai:inrepo02.dkfz.de:294330$$popenCost$$pOpenAPC$$pVDB
000294330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7eaaf5131f5096c7ff7de12dde4ceca5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000294330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000294330 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000294330 9141_ $$y2024
000294330 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000294330 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000294330 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000294330 915pc $$0PC:(DE-HGF)0125$$2APC$$aDEAL: Elsevier 09/01/2023
000294330 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRENDS CANCER : 2022$$d2023-08-25
000294330 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000294330 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000294330 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000294330 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000294330 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000294330 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000294330 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000294330 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bTRENDS CANCER : 2022$$d2023-08-25
000294330 9202_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x0
000294330 9201_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x0
000294330 9200_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x0
000294330 980__ $$ajournal
000294330 980__ $$aVDB
000294330 980__ $$aI:(DE-He78)D196-20160331
000294330 980__ $$aAPC
000294330 980__ $$aUNRESTRICTED
000294330 9801_ $$aAPC